title: Interview with Frank Ivy Carroll.
abstract: Frank Ivy Carroll received his BS degree in chemistry from Auburn University (AL, USA) in 1957 and was awarded the PhD in chemistry by the University of North Carolina at Chapel Hill (NC, USA) in 1961. He joined the research staff of the Research Triangle Institute (NC, USA) as a Research Chemist and rose steadily to the position of Vice President of the Chemistry and Life Sciences Group, a position he held from 1996-2001. Dr Carroll also served as Director of the Center for Organic and Medicinal Chemistry from 1975-2007. He is presently Distinguished Fellow for Medicinal Chemistry. Dr Carroll has varied research interests, but since 1990, a major thrust of his research efforts has involved development of pharmacotherapies for substance abuse (cocaine, nicotine, methamphetamine, opioids and ethanol) and other CNS disorders. Dr Carroll has published 468 peer-reviewed articles, 33 book chapters and 46 patents and has received numerous awards for his research accomplishments; the most recent are: the 2010 North Carolina Award for Science; the 2010 National Institute on Drug Abuse Public Service Award for Significant Achievement; and the 2012 Alfred Burger Award in Medicinal Chemistry from the American Chemical Society. In 2007, he was inducted into the American Chemical Society Medicinal Chemistry Hall of Fame. Interview conducted by Hannah Coaker, Assistant Commissioning Editor.
authors.forename: Frank Ivy
authors.initials: FI
authors.lastname: Carroll
authors.forename: Hannah
authors.initials: H
authors.lastname: Coaker
mesh_terms: D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000737:chemistry / Q000378:metabolism; D003042:Cocaine / Q000378:metabolism / Q000633:toxicity; D018765:Dopamine Uptake Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D009538:Nicotine / Q000378:metabolism / Q000633:toxicity; D011485:Protein Binding; D011725:Pyridines / Q000737:chemistry / Q000378:metabolism; D043704:Receptor, Adenosine A2B / Q000737:chemistry / Q000378:metabolism; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000378:metabolism; D012106:Research; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000473:pathology / Q000517:prevention & control*; D014326:Tropanes / Q000737:chemistry / Q000627:therapeutic use
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; D018765:Dopamine Uptake Inhibitors; D011725:Pyridines; D043704:Receptor, Adenosine A2B; D011978:Receptors, Nicotinic; D014326:Tropanes; D009538:Nicotine; D003042:Cocaine; C082748:epibatidine